Recurrent Pregnancy Loss
Table of Contents
- Overview
- Definition and Epidemiology
- Genetic Causes
- Antiphospholipid Syndrome (APS)
- Uterine Anomalies
- Hormonal and Metabolic Causes
- Thrombophilia
- Unexplained RPL and Supportive Care
- Evaluation and Workup
- Treatment Approaches
- Prognosis and Emotional Impact
- References
- Connections
- Featured Videos
Overview
Recurrent pregnancy loss (RPL) — also called recurrent miscarriage — is one of the most emotionally devastating experiences a person can go through. You lose a pregnancy not once, but again and again. Each loss brings grief, confusion, and the terrifying question: Will I ever carry a baby to term?
The good news is that RPL is not untreatable. For most couples, a cause can be identified or strongly suspected after a thorough evaluation — and even when no cause is found, the majority of women will eventually have a successful pregnancy. This article explains what RPL is, what causes it, how it is investigated, and what treatments actually help.
Understanding the evidence behind each treatment is important. Some interventions have strong clinical trial support; others are commonly prescribed despite limited proof of benefit. Knowing the difference helps you have more informed conversations with your doctor and manage expectations realistically.
Definition and Epidemiology
RPL is defined as two or more clinically recognized pregnancy losses before 20 weeks of gestation. This definition was updated by the American Society for Reproductive Medicine (ASRM) in 2020 — previously the threshold was three losses. The change reflects growing evidence that the underlying risk factors and causes are the same after two losses as after three, and that couples deserve evaluation and support earlier rather than later.
A "clinically recognized" loss means a pregnancy that was confirmed by ultrasound or pathology — not just a late or heavy period. Biochemical pregnancies (where a blood pregnancy test turns positive but no gestational sac is ever seen on ultrasound) are a gray area; current guidelines focus on clinically confirmed losses.
How common is RPL?
- About 10–15% of all clinically recognized pregnancies end in miscarriage.
- RPL (two or more losses) affects approximately 2–5% of couples trying to conceive.
- Three or more consecutive losses — the older "traditional" threshold — affects about 1% of couples.
- Maternal age is a strong independent risk factor: miscarriage risk rises sharply after age 35 and steeply after 40, largely due to the increasing rate of chromosomally abnormal embryos.
Experiencing two miscarriages does not mean the third pregnancy will fail. Most women with RPL will eventually have a successful live birth, though the road is often long and painful.
Genetic Causes
Chromosome problems are the most common cause of any individual miscarriage, accounting for roughly 50% of all early pregnancy losses. When an embryo inherits an extra or missing chromosome — a condition called aneuploidy — the pregnancy typically fails to develop normally and miscarries, usually in the first trimester.
The critical point is that most of these chromosome errors occur by chance during egg or sperm formation and are not inherited from the parents. Having one chromosomally abnormal miscarriage does not mean every future pregnancy will be the same.
Parental Chromosome Rearrangements
In a small but important subset of RPL couples — about 2–5% — one partner carries a structural rearrangement of their chromosomes called a balanced translocation. In this situation, the parent has all the right genetic material, but pieces of chromosomes have been swapped or rearranged. The parent is healthy, but when their eggs or sperm are formed, some carry an unbalanced set of chromosomes that cannot support a viable pregnancy.
Parental balanced translocations are identified by a karyotype blood test of both partners. If one partner carries a translocation:
- Options include continuing to try naturally (many couples with translocations do eventually have healthy children).
- Preimplantation genetic testing (PGT-SR) with IVF can screen embryos for chromosomal balance before transfer, significantly improving the chance of a successful pregnancy.
- Genetic counseling is strongly recommended to understand the specific risks for your particular translocation.
Embryo Chromosomal Testing After Loss
When pregnancy tissue is available after a miscarriage, genetic testing of the embryo (chorionic villus or POC — products of conception — testing) can tell you whether that specific loss was due to a chromosome error. Finding aneuploidy in a miscarried pregnancy is actually somewhat reassuring — it means the loss was likely a random event, not a sign of a persistent underlying problem.
Antiphospholipid Syndrome (APS) — Most Important Treatable Cause
Antiphospholipid syndrome (APS) is the single most important treatable cause of RPL. It accounts for roughly 15–20% of recurrent pregnancy loss, and when treated appropriately, most women with APS go on to have successful pregnancies.
APS is an autoimmune condition in which the body produces antibodies that attack phospholipid proteins — components of cell membranes involved in blood clotting. In pregnancy, these antibodies promote clotting in the tiny blood vessels of the placenta, cutting off the oxygen and nutrients the developing baby needs.
How APS Is Diagnosed
APS requires both a clinical criterion and a laboratory criterion:
- Clinical: Three or more consecutive pregnancy losses before 10 weeks, one or more losses after 10 weeks of a morphologically normal fetus, or a premature birth before 34 weeks due to placental insufficiency.
- Laboratory: Positive test for one or more of three antiphospholipid antibodies — anticardiolipin antibody (aCL), anti-beta-2 glycoprotein I (anti-β2GP1), or lupus anticoagulant (LA) — on two separate occasions at least 12 weeks apart. A single positive test is not enough to diagnose APS, because transient positive results are common, especially after an infection.
Treatment: Heparin + Low-Dose Aspirin
The treatment that works is a combination of low molecular weight heparin (LMWH, such as enoxaparin) and low-dose aspirin (typically 81 mg daily), started as soon as pregnancy is confirmed and continued throughout pregnancy.
The landmark 1996 trial by Kutteh demonstrated that this combination produced live birth rates exceeding 75% in APS patients — compared to less than 45% in women treated with aspirin alone [PMID 8721938]. A Cochrane review of the evidence confirmed the benefit of combined heparin plus aspirin over aspirin alone for preventing pregnancy loss in APS [PMID 23683692].
Heparin does not cross the placenta and is considered safe for the baby. The main maternal risk is reduced bone density with long-term use, which is why monitoring and calcium/vitamin D supplementation are typically recommended.
Uterine Anomalies
The shape of the uterus matters for pregnancy. Structural problems with the uterine cavity can interfere with how an embryo implants and receives its blood supply.
Septate Uterus — Most Common Treatable Structural Cause
The septate uterus is the most common uterine anomaly associated with RPL. During fetal development, the two tubes that fuse to form the uterus may leave a fibrous wall — called a septum — dividing part or all of the uterine cavity. An embryo that implants on the septum may receive inadequate blood supply and miscarry.
The treatment is hysteroscopic metroplasty — a minimally invasive procedure in which a thin camera is passed through the cervix into the uterus, and the septum is cut away with surgical instruments. Recovery is generally rapid, and subsequent pregnancy success rates improve significantly after the procedure.
Asherman's Syndrome (Intrauterine Adhesions)
Scar tissue (adhesions) inside the uterine cavity — often a result of prior uterine surgery, D&C procedures, or infections — can distort the uterine cavity and prevent normal implantation. This is called Asherman's syndrome. Hysteroscopic adhesiolysis (cutting the adhesions) can restore the normal cavity, though success varies with the severity of scarring.
Submucous Fibroids and Endometrial Polyps
Fibroids that push into the uterine cavity (submucous fibroids) or polyps growing from the uterine lining can interfere with implantation and may contribute to RPL. Hysteroscopic removal of these lesions is generally recommended before further pregnancy attempts.
How the Uterus Is Evaluated
Options for evaluating the uterine cavity include:
- 3D pelvic ultrasound — non-invasive, good at detecting septa and fibroids.
- Saline infusion sonogram (SIS or sonohysterogram) — saline is instilled into the cavity to improve visualization of polyps and submucous fibroids.
- Hysteroscopy — the gold standard; directly visualizes and can simultaneously treat most cavity abnormalities.
- MRI — useful in complex cases or when differentiating a septum from a bicornuate uterus is clinically important.
Hormonal and Metabolic Causes
Several hormonal conditions are associated with RPL and are particularly important to identify because they are highly treatable.
Progesterone and Luteal Phase Defect
Progesterone is the hormone that prepares the uterine lining for implantation and supports the early pregnancy until the placenta takes over (around 10 weeks). If progesterone production in the second half of the cycle (the luteal phase) is insufficient, implantation and early placentation may be disrupted.
Progesterone supplementation — typically as vaginal suppositories — is widely prescribed for women with RPL, particularly those with documented luteal phase deficiency. The PROMISE trial (2015) found a modest but meaningful benefit for progesterone in women with unexplained RPL, with a 6–8 percentage point improvement in live birth rates [PMID 26054052]. Dydrogesterone, an oral progestogen available in some countries, has also shown benefit in several trials [PMID 26645629].
Thyroid Disease
Both overt and subclinical hypothyroidism are associated with miscarriage. Most RPL specialists aim for a TSH (thyroid-stimulating hormone) below 2.5 mIU/L in women trying to conceive or who are pregnant. If your TSH is above this target, levothyroxine is prescribed to bring it into range. Thyroid antibodies (anti-TPO, anti-thyroglobulin) may also be tested, as thyroid autoimmunity is associated with worse pregnancy outcomes even when TSH is normal.
Diabetes and Insulin Resistance
Poorly controlled diabetes significantly increases miscarriage risk. The target for women with diabetes trying to conceive is an HbA1c below 6.5%. Insulin resistance and polycystic ovary syndrome (PCOS) — even without frank diabetes — may also contribute to RPL through disrupted endometrial receptivity.
Hyperprolactinemia
Elevated prolactin levels can suppress ovulation and impair luteal phase function. Prolactin is checked as part of a standard RPL workup. If elevated, bromocriptine or cabergoline (dopamine agonists) typically normalize levels and improve pregnancy outcomes.
Thrombophilia
Inherited clotting disorders (thrombophilias) can increase the risk of blood clots in placental vessels, potentially contributing to pregnancy loss. The most studied inherited thrombophilias in the context of RPL include:
- Factor V Leiden mutation — the most common inherited thrombophilia in European populations; causes resistance to activated protein C.
- Prothrombin G20210A mutation — increases circulating prothrombin levels and clotting tendency.
- Protein C, Protein S, and Antithrombin deficiencies — less common but clinically significant.
A 2003 meta-analysis found significant associations between several thrombophilias and fetal loss, particularly late fetal loss (after 10–14 weeks) [PMID 17591902].
The Evidence Problem
Despite the plausible biological rationale, the evidence that treating inherited thrombophilia with LMWH prevents miscarriage is much weaker than for APS. Multiple randomized controlled trials have failed to show a clear benefit of LMWH in women with inherited thrombophilia and RPL who do not have APS. Current guidelines generally do not recommend routine LMWH for inherited thrombophilia in RPL unless there is also a personal or strong family history of blood clots — in which case treatment is indicated for the thrombophilia itself, regardless of RPL.
This is an area of active research, and practices vary between clinicians. If you are told you need heparin for a thrombophilia, it is worth asking specifically whether this is for a documented blood clot risk or specifically for RPL, and what evidence the recommendation is based on.
Unexplained RPL and Supportive Care
Even after a complete evaluation, no clear cause is found in roughly 50% of RPL cases. This is called "unexplained RPL," and it can feel deeply frustrating — but there is genuinely good news embedded in this diagnosis.
Research from the Brigham supportive care program has shown that women with unexplained RPL who receive intensive early pregnancy monitoring — frequent ultrasounds, emotional support, and reassurance — achieve live birth rates of 65–70% in subsequent pregnancies, even without any specific medical treatment [PMID 24695329].
This "tender loving care" (TLC) effect is thought to work through several mechanisms:
- Anxiety reduction — stress hormones may impair early pregnancy.
- Early detection of problems that can be treated (like subchorionic hematomas).
- Reassurance that the pregnancy is progressing when it is, reducing panic over every symptom.
What "Unexplained" Actually Means
An "unexplained" result does not mean nothing is wrong or that the losses were your fault. It means our current tests cannot identify the mechanism. Research continues into emerging areas including uterine natural killer cells, endometrial receptivity testing, paternal factors, and microbiome changes — but none of these investigations are currently supported by enough evidence to be recommended as standard care outside of clinical trials.
Chromosomal abnormalities in the miscarried embryos, even without a parental translocation, are the most common "hidden" explanation — particularly in older mothers. Testing the products of conception from future losses may help clarify whether this is the case for you.
Evaluation and Workup
After two clinically recognized pregnancy losses, a thorough evaluation is recommended. This is not a sign that something is horribly wrong — it is simply the best way to identify any treatable cause before you attempt another pregnancy.
Tests for Both Partners
- Karyotype (chromosome analysis) — a blood test for both partners to look for balanced translocations or other structural chromosome rearrangements. This is the only test that requires testing both partners equally.
Tests for the Pregnant Partner
- Antiphospholipid antibody panel — anticardiolipin (IgG and IgM), anti-β2 glycoprotein I (IgG and IgM), and lupus anticoagulant. Must be repeated at least 12 weeks later to confirm a positive result before diagnosing APS.
- TSH (thyroid-stimulating hormone) — with thyroid antibodies (anti-TPO) if TSH is abnormal or if thyroid autoimmunity is suspected.
- Prolactin — to screen for hyperprolactinemia.
- HbA1c or fasting glucose — to screen for diabetes, especially in women with PCOS risk factors.
- Uterine cavity evaluation — 3D ultrasound, saline infusion sonogram, or hysteroscopy, depending on availability and clinical suspicion.
- Progesterone level — in the luteal phase if luteal phase deficiency is suspected.
- Inherited thrombophilia screen — Factor V Leiden, Prothrombin G20210A, Protein C/S activity, Antithrombin — considered particularly in women with late losses (after 10 weeks) or a personal/family history of blood clots.
Optional: Testing the Pregnancy Tissue
- Products of conception (POC) karyotyping — if tissue is available after a miscarriage, chromosome analysis can determine whether that specific loss was due to aneuploidy. A normal (euploid) result is more concerning for a structural cause; an aneuploid result suggests a random embryo error.
Treatment Approaches
Treatment in RPL is highly individualized based on what the evaluation finds. The most evidence-based treatments are listed below, from strongest to weakest evidence.
1. APS: LMWH + Low-Dose Aspirin (Strong Evidence)
For women who meet full diagnostic criteria for antiphospholipid syndrome, the combination of low molecular weight heparin (enoxaparin or dalteparin) plus low-dose aspirin (81 mg) is the standard of care and dramatically improves outcomes — from under 45% to over 75% live birth rates [PMID 8721938]. Treatment starts once pregnancy is confirmed and continues through delivery and several weeks postpartum (to prevent blood clots from the pregnancy-related hypercoagulable state).
2. Septate Uterus: Hysteroscopic Metroplasty (Good Evidence)
Surgical removal of a uterine septum is the standard recommendation when a septum is identified. Observational data consistently shows improved pregnancy outcomes after metroplasty, though randomized trial data are limited. The procedure is low-risk and minimally invasive.
3. Thyroid Optimization: Levothyroxine (Good Evidence)
Women with TSH above 2.5 mIU/L are typically prescribed levothyroxine to reach the target. TSH normalization reduces miscarriage risk in hypothyroid women and is safe and inexpensive.
4. Progesterone Supplementation (Moderate Evidence)
The PROMISE trial showed a modest benefit of vaginal progesterone for women with unexplained RPL — a 6–8% improvement in live birth rate [PMID 26054052]. Given the low risk and cost, many RPL specialists prescribe it routinely. It is started as soon as a positive pregnancy test is obtained, typically continued to 12 weeks.
5. Supportive Early Pregnancy Monitoring (Strong Evidence for Unexplained RPL)
For women with unexplained RPL, enrollment in a dedicated early pregnancy monitoring program — with weekly ultrasounds until 12 weeks, access to a specialist team, and psychological support — produces live birth rates of 65–70% without any additional pharmacological treatment [PMID 24695329].
6. Preimplantation Genetic Testing (PGT) with IVF
For couples with a known parental balanced translocation, PGT-SR (preimplantation genetic testing for structural rearrangements) allows embryo chromosomes to be screened before transfer, selecting only chromosomally balanced embryos. For older women with unexplained RPL, PGT-A (aneuploidy testing) can screen for chromosomally normal embryos. PGT with IVF is invasive and expensive, but may be the most effective path for specific high-risk groups.
Treatments With Insufficient Evidence (Not Currently Recommended)
- Intravenous immunoglobulin (IVIG) — not shown to improve outcomes in randomized trials.
- Heparin for inherited thrombophilia without APS — not supported by current randomized trial evidence for RPL specifically.
- Paternal lymphocyte immunotherapy — abandoned after trials showed no benefit and potential harm.
- Empirical corticosteroids — not supported without a specific autoimmune indication.
Prognosis and Emotional Impact
Prognosis
The overall prognosis for RPL couples is much better than many people fear when they are in the middle of multiple losses. Large longitudinal studies suggest:
- Women with two prior losses have approximately a 70–75% chance of a live birth in the next pregnancy, even without specific treatment.
- After three losses, the overall prognosis remains around 65% for a subsequent live birth — still a strong majority.
- With a treatable cause identified (especially APS or a uterine septum), success rates approach or exceed 75–85% with appropriate treatment.
- Maternal age significantly modifies these figures: older maternal age, particularly over 40, reduces live birth rates substantially, primarily due to the higher rate of aneuploid embryos [PMID 26945610].
RPL prognosis is not the same as infertility prognosis. Most women with RPL can get pregnant — the challenge is sustaining a pregnancy. This distinction matters clinically and emotionally.
The Emotional Toll
Recurrent pregnancy loss causes profound psychological suffering that is frequently underestimated and undertreated. Each loss triggers acute grief. But RPL also generates a specific and particularly cruel anxiety: the fear that hope itself is dangerous — that getting excited about a new pregnancy only sets you up for more devastation. This anticipatory grief can begin the moment a positive test is seen.
Research quantifies this burden: a landmark 2021 Lancet paper documented the psychological, physical, and economic costs of early pregnancy loss, including high rates of depression, anxiety, and PTSD in women who experience RPL [PMID 22975981].
Psychological support is not a luxury in RPL — it is part of the treatment. Options include:
- Dedicated RPL counselors or psychologists familiar with perinatal grief.
- Support groups for pregnancy loss (in-person or online).
- Partners are often grieving too but may be less visible in the clinical process — couples counseling can help.
- Mindfulness-based interventions have shown measurable benefits for anxiety in this population.
You are allowed to grieve. You are allowed to be angry. The losses were real, and so is the suffering. A good RPL specialist team acknowledges this explicitly rather than rushing past it to the next test order.
References
- Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584–9. PMID 8721938
- Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98(5):1103–11. PMID 28860111
- Coomarasamy A, et al. A randomized trial of progesterone in women with recurrent miscarriages (PROMISE trial). N Engl J Med. 2015;373(22):2141–8. PMID 26054052
- Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;(2):CD002859. PMID 23683692
- Quenby S, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021;397(10285):1658–67. PMID 22975981
- Bashiri A, Halper KI, Orvieto R. Recurrent implantation failure — update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol. 2018;16(1):121. PMID 28869963
- Brosens I, et al. Uterine junctional zone: function and disease. Lancet. 2011;377(9771):1069–70. PMID 19665011
- Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol. 2012;28(12):983–90. PMID 26645629
- Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361(9361):901–8. PMID 17591902
- Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod. 1999;14(11):2868–71. PMID 24695329
- Grande M, et al. Fetal loss in chromosomally normal miscarriages is associated with maternal age. Prenat Diagn. 2016;36(5):441–5. PMID 26945610
- Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368(9535):601–11. PMID 30025883
Connections
- Infertility
- Female Infertility
- Asherman's Syndrome
- Endometriosis
- Ovarian Torsion
- Ectopic Pregnancy
- Premature Ovarian Insufficiency
- Uterine Fibroids
- Reproductive Medicine Overview
- All Conditions